SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Thor Straten Per)
 

Sökning: WFRF:(Thor Straten Per) > Acquired immune res...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004947naa a2200553 4500
001oai:lup.lub.lu.se:95d483b6-e0e8-401a-a0d0-bf17b6061b15
003SwePub
008171010s2017 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/95d483b6-e0e8-401a-a0d0-bf17b6061b152 URI
0247 a https://doi.org/10.1158/0008-5472.CAN-16-31722 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Donia, Marcou University of Copenhagen,Copenhagen University Hospital4 aut
2451 0a Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling
264 1c 2017
300 a 5 s.
520 a Cancer immunotherapy can result in durable tumor regressions in some patients. However, patients who initially respond often experience tumor progression. Here, we report mechanistic evidence of tumoral immune escape in an exemplary clinical case: a patient with metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic complete regression after T-cell–based immunotherapy. Functional cytotoxic T-cell responses, including responses to one mutant neoantigen, were amplified effectively with therapy and generated durable immunologic memory. However, these immune responses, including apparently effective surveillance of the tumor mutanome, did not prevent recurrence. Alterations of the MHC class I antigen-processing and presentation machinery (APM) in resistant cancer cells, but not antigen loss or impaired IFNγ signaling, led to impaired recognition by tumor-specific CD8þ T cells. Our results suggest that future immunotherapy combinations should take into account targeting cancer cells with intact and impaired MHC class I–related APM. Loss of target antigens or impaired IFNγ signaling does not appear to be mandatory for tumor relapse after a complete radiologic regression. Personalized studies to uncover mechanisms leading to disease recurrence within each individual patient are warranted.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Harbst, Katjau Lund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Melanoma Genomics,Lund Melanoma Study Group,Lund University Research Groups4 aut0 (Swepub:lu)med-kbn
7001 a van Buuren, Marit Mu Neon Therapeutics,Netherlands Cancer Institute4 aut
7001 a Kvistborg, Piau Netherlands Cancer Institute4 aut
7001 a Lindberg, Mattias F.u University of Gothenburg4 aut
7001 a Andersen, Rikke Dorotheau Copenhagen University Hospital4 aut
7001 a Idorn, Manjau Copenhagen University Hospital4 aut
7001 a Ahmad, Shamaila Muniru Copenhagen University Hospital4 aut
7001 a Ellebæk, Evau Copenhagen University Hospital4 aut
7001 a Mueller, Anjau Martin-Luther-Universität Halle-Wittenberg4 aut
7001 a Fagone, Paolou University of Catania4 aut
7001 a Nicoletti, Ferdinandou University of Catania4 aut
7001 a Libra, Massimou University of Catania4 aut
7001 a Lauss, Martinu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Melanoma Genomics,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)med-mlu
7001 a Hadrup, Sine Rekeru Copenhagen University Hospital,Technical University of Denmark4 aut
7001 a Schmidt, Henriku Aarhus University Hospital4 aut
7001 a Andersen, Mads Haldu Copenhagen University Hospital4 aut
7001 a Thor Straten, Peru Copenhagen University Hospital4 aut
7001 a Nilsson, Jonasu Netherlands Cancer Institute4 aut
7001 a Schumacher, Ton Nu University of Gothenburg4 aut
7001 a Seliger, Barbarau Martin-Luther-Universität Halle-Wittenberg4 aut
7001 a Jönsson, Göranu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-gjo
7001 a Svane, Inge Marieu Copenhagen University Hospital4 aut
7102 a University of Copenhagenb Copenhagen University Hospital4 org
7730 t Cancer Researchg 77:17, s. 4562-4566q 77:17<4562-4566x 0008-5472
8564 u http://dx.doi.org/10.1158/0008-5472.CAN-16-3172y FULLTEXT
8564 8u https://lup.lub.lu.se/record/95d483b6-e0e8-401a-a0d0-bf17b6061b15
8564 8u https://doi.org/10.1158/0008-5472.CAN-16-3172

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy